Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma. The company has collaborations with Novo Nordisk to evaluate PharmaShell technology; and Moderna for the development of pharmaceutical products with active substances. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
Metrics to compare | NANEXA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNANEXAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −54.0x | −51.3x | −0.5x | |
PEG Ratio | −0.90 | 0.80 | 0.00 | |
Price/Book | 6.1x | 4.1x | 2.6x | |
Price / LTM Sales | 11.0x | 1.1x | 3.2x | |
Upside (Analyst Target) | - | 0.0% | 47.4% | |
Fair Value Upside | Unlock | −23.6% | 7.7% | Unlock |